Pfirmann P, Combe C, Rigothier C
Service de néphrologie, transplantation, dialyse et aphérèses, hôpital Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux, France; Inserm U1026, BioTis, université de Bordeaux, 33076 Bordeaux, France.
Service de néphrologie, transplantation, dialyse et aphérèses, hôpital Pellegrin, CHU de Bordeaux, place Amélie-Raba-Léon, 33076 Bordeaux, France; Inserm U1026, BioTis, université de Bordeaux, 33076 Bordeaux, France.
Rev Med Interne. 2021 Oct;42(10):714-721. doi: 10.1016/j.revmed.2021.03.003. Epub 2021 Apr 6.
Tuberous sclerosis complex (TSC) is an autosomal dominant disorder that affects different organs and caused by loss-of-function mutations in one of two genes: TSC1 or TSC2. TSC1 or TSC2 gene mutation lead to dysfunction of hamartin or tuberin, respectively. Hamartin and tuberin form a protein complex that helps regulate cellular proliferation. These proteins form a complex that constitutively inhibits the mammalian target of rapamycin (mTOR) signaling pathway, leading to permanent activation of mTOR signaling within all TSC-associated lesions. Major features of TSC include tumors of the brain, skin, heart, lungs and kidneys, seizures and TSC-associated neuropsychiatric disorders, which can include autism spectrum disorder and cognitive disability. These disorders are usually diagnosed in children and adults. Specific guidelines for diagnosis, surveillance, and management have been proposed by the International Tuberous Sclerosis Complex Consensus Group. Several randomized controlled trials led to regulatory approval of the use of mTOR inhibitors for the treatment of renal angiomyolipomas, brain subependymal giant cell astrocytomas, refractory epilepsy and pulmonary lymphangioleiomyomatosis.
结节性硬化症(TSC)是一种常染色体显性疾病,可影响不同器官,由TSC1或TSC2这两个基因之一的功能丧失性突变引起。TSC1或TSC2基因突变分别导致错构瘤蛋白或结节蛋白功能障碍。错构瘤蛋白和结节蛋白形成一种有助于调节细胞增殖的蛋白质复合物。这些蛋白质形成一个复合物,持续抑制雷帕霉素哺乳动物靶标(mTOR)信号通路,导致所有TSC相关病变内的mTOR信号通路永久激活。TSC的主要特征包括脑、皮肤、心脏、肺和肾脏肿瘤、癫痫发作以及TSC相关的神经精神疾病,其中可能包括自闭症谱系障碍和认知障碍。这些疾病通常在儿童和成人中被诊断出来。国际结节性硬化症共识小组已经提出了诊断、监测和管理的具体指南。几项随机对照试验促使监管部门批准使用mTOR抑制剂治疗肾血管平滑肌脂肪瘤、脑室管膜下巨细胞星形细胞瘤、难治性癫痫和肺淋巴管平滑肌瘤病。